NCT06788912 2026-03-10
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2 Recruiting
Clinical Trials
8 trialsNCT06116578 2025-12-01
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT04727307 2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2 Recruiting
NCT05296746 2025-03-18
RIBOLARIS
SOLTI Breast Cancer Research Group
Phase 2 Recruiting
NCT05724329 2024-09-19
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT02978222 2022-12-15
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Marker Therapeutics, Inc.
Phase 2 Terminated
NCT02576561 2017-10-25
Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL
THEVAX Genetics Vaccine
Phase 2 Unknown
NCT00693615 2016-09-16
Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females
GlaxoSmithKline
Phase 2 Completed